IMPROVING MEDICATION ADHERENCE IN HYPERTENSION: WHAT PHYSICIANS CAN DO

Abstract

According to the definition of the World Health Organization (WHO), "adherence" is understood as the degree of compliance of the patient's behavior with the recommendations received from the doctor regarding the intake of drugs, adherence to lifestyle changes [1]. Closely related to adherence is another parameter: persistence or constancy of taking therapy in the recommended regimen. This indicator reflects the time during which the patient takes the recommended therapy in strict accordance with the recommendations given to him. It is generally accepted that persistence of 80% or more reflects the high adherence of the patient to the therapy regimen prescribed by the doctor [2].

References

1. World Health Organisation (2003): Adherence to long-term therapies, evidence for action. Geneva: http://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf.
2. Spence JD, Hurley TC, Spence JD. Actual practice in hypertension: implications for persistence with and effectiveness of therapy. Current Hypertension Reports. 2001;3:481-7. doi:10.1007/s11906-001-0010-1.
3. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 2005;353(5):487-97. doi:10.1056/NEJMra050100.
4. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur. Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.
5. Saguner AM, Dür S, Perrig M, et al. Risk factors promoting hypertensive crises: evidence from a longitudinal study. Am. J. Hypertens. 2010;23(7):775-80. doi:10.1038/ajh.2010.71.
6. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35. doi:10.1161/CIRCULATIONAHA.108.768986.
7. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610-8. doi:10.1097/HJH. 0b013e328342ca97.
8. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. doi:10.1016/S0140-6736(02)11911-8.
9. Morin L, Johnell K, LarocheML, et al. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289-98. doi:10.2147/CLEP.S153458.
10. Qvarnstrom M, Kahan T, Kieler H, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69:1955-64. doi:10.1007/s00228-013-1555-z.
11. Mukete BN, Ferdinand KC. Polypharmacy in older adults with hypertension: a comprehensive review. J Clin Hypertens. 2016;18:10-8. doi:10.1111/jch.12624.
12. Luchsinger JA, Honig LS, Tang MX, Devanand DP. Depressive symptoms, vascular risk factors, and Alzheimer’s disease. Int J Geriatr Psychiatry. 2008;23:922-8. doi:10.1002/gps.2006.
13. Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population-based cohort study. J Am Heart Assoc. 2017;6:e006056. doi:10.1161/JAHA.117.006056.
14. Parati G, Kjeldsen S, Coca A, et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. Hypertension. 2021;77:692-705. doi:10.1161/HYPERTENSIONAHA.120.15781.